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In vitro incubation of bone marrow cells with cytokines has been used as an approach to expand stem cells and to facilitate retroviral integration. Expansion of hematopoietic progenitor cells has been monitored by different in vitro assays and in a few instances by in vivo marrow renewal in myeloablated hosts. This is the first report of studies, using two competitive transplant models, in which cytokine-treated cells, obtained from nonpretreated donors (eg, 5-fluorouracil), were competed with normal cells. A basic assumption is that the expansion of progenitors assayed in vitro as highand low-proliferative potential colony-forming cells (HPPand LPP-CFCs) indicates an expansion of stem cells which will repopulate in vivo. This study shows that culture of marrow cells with four cytokines (stem cell factor, interleukin-3 [IL-31. IL-6.11-11) induces significant expansion and proliferation of HPP-CFC and LPP-CFC. Cell-cycle analysis showed that these hematopoietic progenitors were induced to actively cell cycle by culture with these cytokines. In the first competitive transplant model, which uses Ly5.2/Ly5.1 congenic mice, cytokine-cultured Ly5.2 cells competed with HORT-TERM in vitro incubation of murine or human S marrow cells with a variety of single cytokines or growth factor combinations results in expansion of hematopoietic progenitor cells (HPC) as assayed in in vitro colony systems including multipotent colony-forming cells, longterm culture-initiating cells (LTC-IC), and low-and highproliferative potential colony-forming cells (LPP-and HPPCFCs). In a few instances in vivo long-term repopulation has been assesed,'.'' but not compared with normal unmanipulated marrow in a competitive transplant model. Similar in vitro cytokine incubations have been used to cycle hematopoietic cells to facilitate retroviral integration in various gene therapy
Using a marrow transplant model employing normal nonirradiated host mice we have previously shown that cytokine exposure in vitrol5 or administration of fluorouracil (5-FU) in vivo16 results in markedly impaired long-term engraftment of these cells. In each of these experimental models (in vitro cytokines or in vivo 5-Fu) the cell progenitor populations assessed by in vitro colony growth of HPP-CFC and LPP-CFC have been stimulated to proliferate. These studies were performed using a relatively unique transplant model in which donor cell populations engraft into nonlymphomyeloablated hosts. Assessment of long-term repopulating ability is usually performed in myeloablated hosts and virtually all transplant and stem cell models have used irradiated myeloablated hosts. This is the first report of two competitive studies in which cytokine-treated cells, which were not obtained after chemotherapy (eg, day 2 post 5-FU), were competed with noncultured fresh marrow cells in lethally irradiated recipients. We have evaluated the effects of in vitro culture of marrow cells with interleukin-3 (IL-3), IL-6, IL-11 and stem cell factor (SCF) on progenitor cell expansion, cell-cycle status, and competitive repopulation in vivo.
MATERIALS AND METHODS
Mice. C57BL/6 (Ly5.2) and B6.SJL (Ly5.1) mice were purchased from The Jackson Laboratories (Bar Harbor, ME), and BALB/c mice were purchased from Charles River Laboratories (Wilmington, MA). All animals were maintained in virus-free conditions and were given food and acidified water ad libitum. Mice were purchased at either 16 to 18 g or 18 to 22 g and were housed for a minimum of 1 week before experimental use.
Culture of bone marrow (BM) with cytokines for 48 hours for expansion. BM cells were obtained by flushing tibias and femurs of 6-to 8-week-old Ly5.2 (C57BL/6) and Ly5.1 (B6.SJL) mice. Ten million BM cells were cultured in nonadherent tissue culture dishes at a density of lo6 nucleated cells/mL in DMEM (low glucose), supplemented with 15% heat-inactivated fetal calf serum (FCS) with cytokines (recombinant murine SCF [nnSCF] at 50 ng/mL, d L -3 at 50 U/mL, rmIL-6 at 50 U/mL, and rhuIL-11 at 50 ng/mL) at 37°C in a fully humidified atmosphere of 5% CO, in air." After 48 hours all cultured cells were procured by vigorous pipetting with ice-cold phosphate-buffered saline (PBS) and cell scraping (as determined by microscopy).
Both freshly procured uncultured cells and cells obtained after 48 hours culture were counted
In vitro agar colony-forming assays.
and plated at a cell density of 25,000 per 35-mm plastic petri dish in a double-layer nutrient agar system. Underlays were a-Modified Eagle's Medium ( a MEM) with 15% FCS supplemented with vitamins, glutamine, and growth factors (colony-stimulating factor [CSF-11, granulocyte-macrophage-CSF [GM-CSF], G-CSF, IL-la, IL-3, mSCF, and basic fibroblast growth factor [bFGF]). Target cells were included in a 0.5-mL overlay with a final agar concentration of 0.33%. Dishes were gassed with a mixture of 5% 0,. 10% CO,, and 85% NI and incubated at 37°C for 14 days. In general, four dishes were set up from each animal. Plates were scored on a dissecting microscope for LPP-CFC (all cell clusters with more than 50 cells and not fulfilling HPP-CFC criteria) and HPP-CFC (highly dense colonies greater than 0.5 mm in diameter or moderately dense colonies greater than 1.0 mm in diameter).15
Tritiated thymidine suicide assay. The in vitro 3HTdR suicide technique was performed as previously de~cribed.'~.'~ Briefly, 5 x lo6 marrow cells per mL were incubated at 37°C for 20 minutes in Hanks' balanced salt solution (HBSS) containing 200 pCi per mL 3H-TdR (New England Nuclear, Boston, MA; specific activity = 20.0 Ci/mmol/L) or a concentration of nonlabeled "cold" thymidine equivalent to that in the 3HTdR incubation. After this incubation excess cold thymidine was added and the cell suspension washed three times and then plated at an equivalent cell density of 25,000 per dish based on the original counts for progenitor cell growth in vitro in soft agar as described above. The fraction of cells in cycle was determined by percent reduction of HPP-CFC induced by 3HTdR exposure.
Competitive BM transplantation of marrow from Ly5.2Ly5. I congenic C57BU6 and B6.SJL mice. Cells were obtained and cultured as described above. Recipient mice were exposed to 12.0 Gy (7.0 Gy and 5.0 Gy given 3 hours apart) in a gamma cell 40 cesium source and 1 hour later injected intravenously (IV) with (1) a mixture of 50% cytokine-cultured Ly5.1 cells (equivalent to 20 X lo6 starting cells harvested after 48 hours of incubation with cytokines) and 50% fresh noncultured Ly5.2 cells; (2) a mixture of 50% noncultured Ly5.1 cells and 50% cytokine-treated Ly5.2 cells (equivalent to 20 X lo6 starting cells harvested after 48 hours of incubation with cytokines); and (3) a mixture of 50% cytokine-cultured cells (equivalent to 20 X lo6 starting cells harvested after 48 hours of incubation with cytokines) of both cell types. Volumes for injection ranged from 0.5 to 1.0 mL. The percentages of marrow cells bearing the Ly5.2 and Ly5.1 phenotypes were determined 12 and 22 weeks posttransplant by fluorescence-activated cell sorter (FACS) analysis. One million suspended cells were incubated for 10 minutes with mouse IgG (Sigma) for 30 minutes at 4°C. The Ly5-specific monoclonal antibodies (MoAbs) for Ly5.2 (fluorescein isothiocyanate [FITCI-conjugated MoAb 1042.1) and Ly5.1 (biotin-conjugated A201.7) (Jackson Immunolaboratories, Bar Harbor, ME) were added for 30 minutes, and then washed twice. Cell-bound biotinylated MoAb A201.7 was detected with streptavidin-Red 670 (R&D, Minneapolis, MN), which was incubated for 30 minutes at 4°C. Cells were washed twice and subsequently analyzed with an FACS (FACS-STAR; Becton Dickinson, San Francisco, CA).
Competitive BM transplantation of male and female BALBk marrow. Cells obtained from BALBk mice were cultured as described above. Female recipient mice were given 10.5 Gy irradiation in doses of 5.5 Gy and 5.0 Gy administered 3 hours apart and 1 hour later injected IV with either a mixture of 50% cytokine-cultured female (corresponding to the equivalent of 20 x lo6 starting cells harvested after 48 hours of culture with cytokines) and 50% (20 x lo6) fresh noncultured male cells, or a mixture of 50% cytokinecultured male cells (corresponding to the equivalent of 20 x IO6 starting cells obtained after 48 hours of culture with cytokines) and 50% (20 X lo6) fresh noncultured female cells. Volumes for injection were the same in each experiment and ranged from 0.5 to 1.0 mL. The percentage of male marrow in host marrow cells was then determined 10 and 14 weeks posttransplantation using Southem blot analysis with the Y-chromosome-specific pY2 probe" performed as described." Briefly, approximately 5 jig of genomic DNA per sample was digested with the restriction enzyme Dra-1 (Boehringer Mannheim, Indianapolis, IN) and separated by gel electrophoresis in 0.8% agarose (GIBCO-BRL, Grand Island, NY). DNA f'ragments were transferred onto Zetaprobe nylon membranes (BioRad, Richmond, CA) by capillary transfer ovemight in 0.4 N sodium hydroxide. The blots were probed for the presence of Y-specific sequences using the pY2-cDNA (courtesy of Dr Ihor Lemischka, Princeton University, Princeton, NJ). Autoradiography was performed on Kodak XRP films (Eastman Kodak, Rochester, NY). The percentage of radioactivity of male and female DNA was quantified by exposing filters to photostimulatable phospor imaging plates (Molecular Dynamics, Sunnyvale, CA) and scanning the plates with a 400 A PhosphorImager (Molecular Dynamics),20 and quantitation was based on comparisons between posttransplant DNA samples and male murine DNA. Calculations of percent DNA were adjusted based on amounts of DNA loaded on each gel as determined by separate probing with an IL-3-specific cDNA (courtesy of J. Ihle and DNAX, Palo Alto, CA).
In both transplant models lethal whole-body irradiation was used. Irradiated female mice were injected with male cells and repopulation with male cells only was seen (data not shown). Similar controls were performed in the Ly5.2Ly5.1 model to exclude contribution from host repopulation.
Statistical analysis. Levels of significance of expansion of noncultured progenitors by cytokine-treatment were analyzed by Wilcoxon's rank sum test.,' Mean differences of percentages of noncultured and cultured progenitors killed by in vitro 3HTdR exposure were compared by standardized-normal tests.,' Differences in engraftment of noncultured and cytokine-treated populations were compared by Wilcoxon's rank sum test.
RESULTS
Effect of culturing BM in growth medium and cytokines IL-3, IL-6, IL-11, and SCF f o r 48 hours on expansion of hematopoietic progenitor cells. Expansion of HPC by culture of marrow in growth medium and cytokines (mSCF at 50 ng/mL, mIL-3 at 50 U / d , mIL-6 at 50 U/mL, and huIL-11 at 50 ng/mL) for 48 hours was determined by comparing the contents of HPP-CFCs and LPP-CFCs of both freshly obtained uncultured marrow and cytokine-treated cells in a soft-agar colony assay. Cultured cells were procured by vigorous pipetting with ice-cold PBS and cell scraping until virtually no residual cells remained in the culture flasks as determined by microscopy. Cultured marrow cells from Ly5.2 (C57BU6) and Ly5.1 (B6.SJL) mice were expanded by 49% and 206% for HPP-CFC and 14% and 166% for LPP-CFC in these murine strains, respectively (Fig 1) . This expansion of cultured progenitors by cytokine-treatment was significant for HPP-CFC and LPP-CFC in Ly5.1 marrow ( P < .01, Wilcoxon's rank sum test), and was marginally significant (P = .l) in Ly5.2 marrow.
Effects of the culture with cytokines on the cell-cycle status of HPC. The cell-cycle status of primitive progenitor cells present in noncultured marrow and in marrow that was incubated for 48 hours in culture medium with the cytokines mSCF, IL-3, IL-6, and IL-11 was analyzed by comparing colony growth of marrow exposed to high activity tritiated thymidine (3HTdR) to colony growth of marrow that was (Fig 2A) . The amount of HPP-CFC and LPP-CFC killed in noncultured fresh marrow by thymidine suicide was a mean of 0% indicating that most HPC were in dormancy. After culture with cytokines a mean of 95% of HPP-CFCs and a mean of 86% of LPP-CFCs were killed by exposure to high-activity tritiated thymidine in these Ly5.2 mice (Fig 2A) . This indicates that most of the cytokine-treated cells had been induced to enter active phases of the cell cycle.
This change of HPC cycle status induced by culture of marrow cells with cytokines was also observed in marrow from Ly5.1 (B6.SJL) mice (Fig 2B) . In this strain 20% of HPP-CFCs and 32% of LPP-CFCs of noncultured marrow were killed by exposure to 'H-TdR. The amount of progenitor cells entering active phases of the cell cycle increased dramatically as shown by HPP-CFC fractions of 98% and LPP-CFC fractions of 86% killed by exposure to high activity tritiated thymidine in this strain. A standardized-normal test comparing the mean differences of noncultured and cultured progenitors was highly significant ( P < .OOOl) in both strains.
Efect of culture with cytokines on engraftnhilih of BM into letltnlly irradiated hosts. We have used two competitive murine transplant models in irradiated host mice to assess for the engraftment potential of marrow cells cultured for 48 hours with the cytokines mSCF, IL-3, IL-6, and IL-1 I . The first model, which uses the LY-5.llLy-5.2 congenic B6.SJL and C57BL/6 strains, allows distinction of donorand host-derived cells with MoAbs specific for the alleles of Ly-5; the second model uses BALB/c mice, allowing for the detection of male donor cell DNA sequences in female recipients.
The equivalent of 20 X IO" starting cells of either Ly5.1 (B6.SJL) or Ly5.2 (C57BL/6) that were obtained after a culture with the cytokines mSCF, IL-3, IL-6, and IL-I I were mixed and injected together with fresh, noncultured cells of the opposite strain into irradiated (12.0 Gy) recipient mice. The percentages of marrow cells stained with MoAbs specific for the two alleles of Ly-5 were determined 12 and 22 weeks posttransplant by FACS analysis (Fig 3) . Noncultured Ly5.2 (C57BW6) marrow, competing with cytokine-cultured Ly5.1 (B6.SJL) marrow, lead to high engraftment with a mean (?SE) of 70% ? 1% (n = IO) in Ly5.1 (Fig 3A) and of 63% ? 5% (n = 5) in Ly5.2 recipients (Fig 3B) at 12 weeks posttransplantation. Engraftment levels of cultured Ly5.2 marrow cells competing with noncultured Ly5.1 cells were 5% ? 1% (n = IO) in LyS.1 recipients (Fig 3A) and 7% ? 2% (n = 5) in LyS.2 recipients (Fig 3B) at 12 weeks posttransplant. Differences in engraftment between noncultured and cytokine-treated populations were significant ( P < .01, Wilcoxon's rank sum test) in the experiment in Ly5.2-recipients and was marginally significant ( P = . l ) in the experiment in Ly5.1 -recipients. This engraftment defect of cytokine-treated marrow was even more pronounced when analyzed 22 weeks after transplantation (Fig 3C) . Mean engraftment of cultured Ly5.2 donor marrow competing with fresh Ly5.1 cells was only 4% t 2% (n = IO) at 22 weeks, six individual mice showing no engrafting cells. Fresh noncultured Ly5.2 marrow competed with cultured Ly5.1-cells gave a mean level of 93% 2% (n = IO) engraftment with three mice showing all LyS.2 cells. Differences in engraftment between noncultured and cytokine-treated populations were significant at 22 weeks posttransplantation ( P < .Ol).
A similar engraftment defect of expanded progenitor cells in active phases of the cell cycle could be shown in the other transplant model that uses male and female BALB/c donor populations into irradiated female BALB/c marrow recipients (Fig 4) . We have previously shown a 2.3-fold increase of LPP-CFCs and maintenance of HPP-CFCs after culture with cytokines for 48 hours.'' Cell-cycle analysis had indicated that 90% of HPP-CFC were induced to enter active phases of cell cycle by activation with cytokines.'' Here we present data from competitive engraftment studies in which the equivalent of 20 X 10" starting male or female cells obtained after a culture with the cytokines mSCF, IL-3, IL- After 48 hours of culture with cytokines, 86% of LPP-CFC and 95% of HPP-CFC were killed. A standardized-normal test comparing the mean differences of noncultured and cultured progenitors was highly significant ( P < .0001) in both strains.
6, and IL-11 were mixed and injected together with fresh, noncultured cells of the opposite gender into irradiated (10.5 Cy) recipient mice. Southem blot engraftment analysis using the Y-chromosome-specific pY2 cDNA probe showed compromised engraftment of cultured cytokine-exposed marrow cells competing with noncultured marrow cells in BM, spleen, and thymus of lethally irradiated female hosts at 10 and 14 weeks posttransplantation. Noncultured male BALB/ c marrow cells, competing with cytokine-cultured female BALB/c marrow, lead to mean engraftment (LSE) levels of 70% 2 2% (n = 5 ) in female BALB/c recipient marrow at 10 weeks posttransplantation (Fig 4A, top row) . Mean engraftment levels of cultured male marrow cells competing with noncultured female cells were 13% L 9% (n = 5) in the marrow of female recipients at 10 weeks. This difference in engraftment of noncultured and cytokine-treated populations is statistically marginally significant (P = .5, Wilcoxon's rank sum test). The engraftment defect was more impressive in animals analyzed 14 weeks after transplantation (Fig 4A, bottom row) . Fresh noncultured male BALB/ c marrow cells competing with cytokine-treated female cells contributed to 95% 2 9% (n = 10) marrow engraftment while cytokine-treated male cells competing with noncultured female cells gave a mean level of only 2% 2 1% (n = 10). Differences in engraftment between non-cultured and cytokine-treated populations were highly significant (P <
.O 1). In these BALB/c transplants the engraftment defect was also apparent when spleen and thymus were analyzed, indicating that this is a general engraftment defect (Fig 4B  and C) .
DISCUSSION
These data show that in vitro exposure to a cytokine cocktail of IL-3, IL-6, IL-11, and SCF expands surrogate progenitordstem cells (LPP-CFC and HPP-CFC) in vitro, induces them to progress through cell cycle, and concomitantly produces a profound engraftment defect in lethally irradiated myeloablated hosts. Studies in both engraftment models show a more profound engraftment defect at longer time intervals posttransplantation, suggesting that the most striking effect may be on the long-term repopulating population.
Cytokine expanded progenitor cells may not be truly renewal stem cells or may retain renewal potential but exist in a nonengrafting state. A number of studies in murine species have shown that multipotential CFCs like GM-CFC, CFU-GEMM, HPP-CFC, and LTC-IC can be expanded in vitro after exposure to a wide variety of cytokine mixtures including SCF, CSF-1, G-CSF, M-CSF, GM-CSF, IL-l a , IL-6, IL-11, erythropoietin, PIXY321, interferon-y, and leukemia inhibitory f a~t o r .~~'~'~'~~~~~* Functional aspects such as increased capacity to form CFU-S3 and augmented capacity for short-and long-term renewal (<35 and 2 3 5 days, respectively) have been assessed for fresh cells competing with "compromised" for fresh cells in noncompetitive transplant studiesz9 and for cells obtained after treatment expanded with cytokines in vivo in anemic and/or irradiated mice. This is the first study in which cytokine-treated normal cells, as opposed to cells harvested after chemotherapy, were competed with normal cells and analyzed for their contribution for engraftment. We show that primitive hematopoietic cells induced to divide and proliferate by cytokines in culture acquire an engraftment defect that is related to cell cycle activation. in culture could alternatively explain this engraftment defect, but it seems unlikely that all of the hematopoietic stem cells, which are constantly exposed to cytokines in vivo, would differentiate out of the stem cell pool. Findings of altered integrin molecule expression related to cytokine-induced cell-cycle transit suggests a possible mechanism for the cytokine-induced engraftment defect related to modulation of homing factors.31 Engraftable states of cultured hematopoietic progenitors may be maintained by cytokines that spare cell cycle activation. This is suggested by data from Li and Johnson' showing maintained long-term repopulating ability of rhodamine 123 low, lineage-negative Ly6AE+ cells for as long as 7 days in culture with SCF when injected with compromised marrow. Protocols designed to promote mitosis of hematopoietic progenitors for retroviral gene transfer frequently contain cytokine combinations including SCF, IL-3, IL-6, and IL-l11.7.1'-'4 rendering them unlikely to engraft. Attempts to alter engraftment efficacy of cytokine treated stem cells by reversing cell-cycle-related defects may be indicated both to improve the clinical potential for cytokine-expanded stem cells and for gene therapy approaches.
